Ruilope Luis, Kjeldsen Sverre E, de la Sierra Alejandro, Mancia Giuseppe, Ruggenenti Piero, Stergiou George S, Bakris George L, Giles Thomas D
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.
Blood Press. 2007;16(2):72-9. doi: 10.1080/08037050701338985.
Cardiovascular and renal diseases share many of the same risk factors. In fact, renal failure is usually accompanied by an increased global cardiovascular risk. Thus, preservation of kidney function might simultaneously protect the heart and the brain and, conversely, addressing cardiovascular risk factors might safeguard the kidney. This review considers the evidence supporting this approach, focusing on the protective effect of blood-pressure lowering and the ancillary actions of antihypertensive agents on renal protection. We review recent evidence on renal protection in individuals with and without diabetes, and the importance of offering a high standard of care also to those with the metabolic syndrome or prediabetes in order to prevent initial forms of renal, and as a consequence, cardiovascular damage. Intervention may be appropriate even in individuals with high-normal blood pressure, if they already have early renal and/or cardiovascular risk markers. As a consequence of these insights, thresholds for starting antihypertensive therapy are gradually falling, whereas awareness of the need for an early intervention in patients at high risk of developing renal damage and simultaneously cardiovascular disease is growing.
心血管疾病和肾脏疾病有许多相同的危险因素。事实上,肾衰竭通常伴随着整体心血管风险的增加。因此,保护肾功能可能同时保护心脏和大脑,反之,控制心血管危险因素可能保护肾脏。本综述考虑了支持这种方法的证据,重点关注降压的保护作用以及抗高血压药物对肾脏保护的辅助作用。我们回顾了近期关于糖尿病患者和非糖尿病患者肾脏保护的证据,以及为代谢综合征或糖尿病前期患者提供高标准护理以预防早期肾脏疾病进而预防心血管损害的重要性。即使血压略高于正常的个体,如果他们已经有早期肾脏和/或心血管风险标志物,进行干预可能也是合适的。基于这些认识,开始抗高血压治疗的阈值正在逐渐降低,而对于有发生肾脏损害和同时发生心血管疾病高风险的患者需要早期干预的认识正在不断提高。